[Form 4] Jasper Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Jasper Therapeutics director Thomas G. Wiggans reported purchases and a sale on Form 4. On 09/22/2025 he acquired 41,000 shares of voting common stock together with warrants to purchase 41,000 additional shares at a combined offering price of $2.43 per share and accompanying warrant through an underwritten public offering. The warrants have an exercise price of $2.92, are exercisable beginning 03/22/2026 and expire 03/22/2030, and the reported holdings are held indirectly by the Wiggans Living Trust.

Separately, the filing shows a disposal of 5,000 shares on the same date. The Form 4 was signed by an attorney-in-fact on 09/24/2025. The filing discloses only these transactions and the trust as the indirect owner; no other financial results or corporate actions are included.

Positive

• Director purchase of 41,000 shares with matching warrants at a combined price of $2.43 per unit, indicating insider participation
• Warrants exercisable at $2.92 through 03/22/2030, providing potential upside if share price rises
• Transaction disclosed as indirect ownership via Wiggans Living Trust, clarifying ownership form

Negative

• Sale of 5,000 shares on the same date reduces the director's net immediate share count
• Filing contains no context on total outstanding shares or size of holding relative to issuer, limiting assessment of materiality

Insights

Securities Analyst

TL;DR: Director participation in the public offering signals personal alignment with the company but is modest relative to public markets.

The report shows Director Thomas G. Wiggans purchased 41,000 shares with matching warrants at a combined price of $2.43 per unit and sold 5,000 shares the same day. Director purchases in an underwritten offering can indicate confidence in the company or be driven by allocation availability; the structure (shares plus one-for-one warrants) provides potential upside if the stock appreciates above the $2.92 exercise price. Holdings are indirect via a trust, which may affect timing and liquidity. Absent company financials or size context, the market impact is likely limited but locally positive.

Corporate Governance Expert

TL;DR: Transaction appears routine and compliant with Section 16 reporting; indirect ownership through a trust is disclosed.

The Form 4 properly reports a director-level participant in an underwritten public offering and a contemporaneous small disposal. Disclosure lists the Wiggans Living Trust as the indirect owner and includes required dates and signature by attorney-in-fact. There are no indications of late reporting or unexplained transfers in the filing text provided. From a governance perspective, the filing meets the basic transparency standards required under Section 16.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

WIGGANS THOMAS G

(Last) (First) (Middle)

C/O JASPER THERAPEUTICS, INC.

2200 BRIDGE PKWY, SUITE #102

(Street)

REDWOOD CITY CA 94065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Jasper Therapeutics, Inc. [ JSPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Voting Common Stock	09/22/2025		P		41,000	A	$2.43(1)	41,000	I	By Wiggans Living Trust
Voting Common Stock								5,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock Warrant (right to buy)	$2.92	09/22/2025		P		41,000		03/22/2026	03/22/2030	Voting Common Stock	41,000	(1)	41,000	I	By Wiggans Living Trust

Explanation of Responses:

1. Each share of voting common stock was purchased together with an accompanying warrant to purchase one share of voting common stock in an underwritten public offering at a combined offering price of $2.43 per share of voting common stock and accompanying warrant.

	/s/ Herb Cross, as Attorney-in-Fact	09/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Jasper Therapeutics (JSPR) insider Thomas G. Wiggans report on Form 4?

He reported acquiring 41,000 shares together with warrants to buy 41,000 additional shares at a combined price of $2.43 per unit and selling 5,000 shares on 09/22/2025.

What are the terms of the warrants reported in the JSPR Form 4?

Each warrant has an exercise price of $2.92, becomes exercisable on 03/22/2026, and expires on 03/22/2030.

How is the reported ownership held according to the Form 4?

The reported 41,000 shares and associated warrants are held indirectly by the Wiggans Living Trust.

When were the transactions and the Form 4 signature dated?

Transactions occurred on 09/22/2025 and the Form 4 was signed by counsel on 09/24/2025.

Does the Form 4 provide financial or operational details about Jasper Therapeutics?

No. The filing only discloses insider transactions and ownership form; it contains no earnings, revenue, or operational data.